Survival of foals with experimentally induced Rhodococcus equi infection given either hyperimmune plasma containing R. equi antibody or normal equine plasma.
The purpose of this study was to determine if colostrum-deprived foals with experimentally induced Rhodococcus equi pneumonia have a decreased severity of the disease and decreased mortality rate when given hyperimmune (HI) R. equi antibody plasma (R. equi titer at least 100 % and virulence-associated protein A [VapA] at least 10000) prophylactically versus when given normal equine plasma (R. equi titer less than 20 % and VapA less than 160). Sixteen colostrum-deprived foals (R. equi titer less than 5 %) each received normal equine plasma in the first 24 hours of life (R. equi titer less than 20 %). At 14 days of age, six foals were given normal equine plasma and 10 foals were given HI plasma. All foals were subsequently infected intrabronchially with a pathogenic strain of R. equi (2.5 x 10 sup 8; organisms) at 21 days of age. Repeated physical examinations, weight measurements, complete blood cell counts, fibrinogen measurements, and thoracic radiographs (ventrodorsal and lateral) were performed to help determine the severity of the disease. Foals given HI plasma had significantly higher R. equi ELISA titers (42.4 %) than those given normal plasma (20.9 %) on the day of experimental infection. Mortality rates and severity of disease were statistically similar (P >.05) for the groups. Although none of the foals was treated with antibiotics, several with severe R. equi pneumonia recovered. Either HI or normal equine plasma administered to foals in the first few weeks of life caused no adverse effects and may be protective against R. equi, although the exact constituent responsible for protection is undetermined and requires further investigation.
Perkins
Gillian A
GA
Cornell University, New York State College of Veterinary Medicine, Department of Clinical Sciences, Ithaca, NY 14853, USA.
Yeager
Amy
A
Erb
Hollis N
HN
Nydam
Daryl V
DV
Divers
Thomas J
TJ
Bowman
James L
JL
D000193:Actinomycetales Infections / Q000276:immunology* / Q000517:prevention & control / Q000662:veterinary*; D000818:Animals; D000907:Antibodies, Bacterial / Q000008:administration & dosage / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006734:Horse Diseases / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control*; D006736:Horses / Q000276:immunology / Q000382:microbiology; D007116:Immunization, Passive / Q000662:veterinary*; D008297:Male; D010949:Plasma / Q000276:immunology; D018410:Pneumonia, Bacterial / Q000276:immunology / Q000401:mortality / Q000517:prevention & control / Q000662:veterinary; D016929:Rhodococcus equi / Q000276:immunology*; D015996:Survival Rate
D000907:Antibodies, Bacterial